The Firm recently represented the underwriters, led by Barclays Capital Inc., Citigroup Global Markets Inc., Deutsche Bank Securities Inc. and J.P. Morgan Securities LLC, in connection with the public offering by Boston Scientific Corporation (“Boston Scientific”) of $1.85 billion of debt securities, consisting of $600 million of 2.85% senior notes due 2020, $500 million of 3.375% senior notes due 2022 and $750 million of 3.85% senior notes due 2025. Boston Scientific will use the net proceeds to finance a portion of the acquisition of the American Medical Systems Urology portfolio of Endo International plc and redeem outstanding senior notes.
Boston Scientific, as a global medical technology leader for more than 35 years, advances science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.
The Simpson Thacher team for the transaction included Roxane Reardon, Alexander Coedo and Christopher Freeman (Capital Markets); Michael Vernace (Banking & Credit); Jonathan Cantor and Jodi Sackel (Tax); Noah Leibowitz, Marcela Robledo and Katherine Helm (Intellectual Property); Michael Isby and Timothy Mulvihill (Environmental); Jeanne Annarumma, Brittany McCants and Alina Grinman (ECEB); and Jennie Getsin (FINRA/Blue Sky).